AMRI’s once troubled Burlington facility has seen an uptick in new contracts and is showing strong potential for more, according to CEO Thomas D'Ambra.
Lonza has brought in a new exec to oversee cost reduction and efficiency efforts at its largest custom API manufacturing plant in what CEO Richard Ridinger calls the Visp challenge.
GE Healthcare has started designing a vaccine manufacturing facility for an unnamed drug company, just days after expanding its collaboration with plant-cell production technology firm iBio.
Industrial gas supplier Linde claims its 'cryogenic fog' technology is the first commercially-feasible way of controlling ice-crystal formation during the lyophilisation of biologic drugs.
Catalent has replaced all stainless steel bioreactors at its biologics facility in Middleton, Wisconsin with single-use techs citing cost and flexibility advantages.
Cherwell Laboratories has more than doubled the size of its Bicester, UK, plant that manufactures prepared media for microbial production after a boom in demand for its goods.
Teva Pharmaceuticals is set to build its first Indian production plant after finalising a pact with healthcare giant Procter & Gamble (P&G), according to local authorities.
Sigma Aldrich’s fine chemicals manufacturing section SAFC ensured a modest growth for the company although its “weak” research business in the US and the EU has stunted any drastic figures, according to analysts.
The global CMO market will grow from $26bn in 2010 to $59.9bn by 2018 thanks to a boom in the amount of work outsourced to the Asia market, says GBI Research.
SPIC has pressed the Indian PM to issue a standardised excise duty to all contract manufacturers operating in the country so drugsmakers can have a level playing field.
Approval of Qsymia - Vivus’ anti-obesity drug – may be good news for the 35 per cent of US citizens classed as obese, but it is definitely good news for Taiwan-based CMO ScinoPharm.
API production in India will take a hit this week with plant closures for Aurobindo, Hetero Drugs, Divis Pharmaceuticals, and Sri Krishna Pharmaceuticals following allegations of environmental wrongdoing.
DSM Pharmaceutical Products (DPP) has won its second biologics manufacturing contract in two months signing up Brazil’s Recepta Biopharma as a new customer.
Ampac gets the OK from the DEA, Syngene lands PE-ED manufacturing contract and Great Southern is bought by Pernix Therapeutics – welcome to Outsourcing-pharma.com’s CMO round-up.
Dishman Pharmaceuticals has abandoned plans to set up a special economic zone (SEZ) citing law changes that make the project less attractive and unfavourable economics as the reasons for the decision.
No job losses, facility divestitures or strategic changes are planned at DPT Laboratories according to new owner Renaissance Pharma, which bought the CDMO in an out-of-the-blue deal last week.
The EMA wants a debate on the extrapolation of clinical data to see if a framework is needed to govern this potential approach to reducing unnecessary research and letting industry use resources more efficiently.
Outsourcing-Pharma.com presents a round-up of the latest contract manufacturing investments, including new screening services for Imaxio, Encap’s renewed push for its CMO biz, and Pernix’s bid to take over Great Southern Laboratories.
The implementation of single use technology in the biopharmaceutical fill and finish process has seen a massive uptick recently because of better industry understanding, according to Pall’s Bruce Rawlings.
A new hand-held testing device can help drugmakers determine if their stainless steel tech is prone to corrosion according to developer Koslow Scientific.
China-based Suzhou Pharma has set up a US regulatory and QA hub in what it says is a bid to provide Western cGMP (current good manufacturing practice) know-how with low cost Asian production.
Catalent and Bend Research have joined forces to tackle time and cost restrictions for the complex oral controlled-release development and manufacturing process.
